A Randomized, Multi-Center Pilot Study to Evaluate the Efficacy and Safety of Epoetin Alfa (Procrit) in the Treatment of HIV-Associated Sensory Neuropathy.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2016
At a glance
- Drugs Epoetin alfa (Primary)
- Indications HIV-associated nephropathy; Neuropathic pain
- Focus Pharmacodynamics
- 12 Feb 2010 Planned end date changed from 1 Feb 2008 to 1 Oct 2009 as reported by ClinicalTrials.gov.
- 01 Jun 2009 New trial record